Melasma: successful treatment with pidobenzone 4% (K5lipogel)

Fabio Zanieri1, Gelareh Bani Assad, Piero Campolmi

  • 1Centro Interuniversitario di Dermatologia Biologica e Psicosomatica, Università Consorziate, Firenze-Milano-Siena, Italy.

Dermatologic Therapy
|September 9, 2008
PubMed

Insights

Pidobenzone 4% lipogel offers a safe and effective treatment for melasma, a common skin hyperpigmentation condition. This study demonstrates its reliability in managing various melasma types, with a low relapse rate.

Area of Science:

  • Dermatology
  • Cosmetic Science

Background:

  • Melasma is an acquired facial hyperpigmentation with unknown etiology, often linked to sun exposure and genetics.
  • It disproportionately affects individuals with darker skin tones, particularly women, and is challenging to treat due to frequent relapses.

Purpose of the Study:

  • To evaluate the safety and efficacy of pidobenzone 4% lipogel in treating melasma.
  • To assess the long-term reliability and relapse rates associated with this treatment.

Main Methods:

  • A study involving the application of pidobenzone 4% (K5 lipogel) twice daily for 16 weeks.
  • Observation and documentation of treatment outcomes across different melasma types.

Main Results:

  • Pidobenzone 4% lipogel demonstrated significant safety and effectiveness in melasma treatment.
  • The treatment proved reliable for various melasma presentations, indicating a potential for reduced recurrence.

Conclusions:

  • Pidobenzone 4% lipogel is a safe, reliable, and effective therapeutic option for diverse melasma presentations.
  • This lipogel formulation offers a promising approach to managing this common and often persistent skin condition.

Related Concept Videos